FDA approves Boston Scientific’s Ranger drug-coated balloon

Boston Scientific (NYSE:BSX) Monday said it received FDA approval for its Ranger drug-coated balloon for peripheral artery disease.

The balloon’s creators designed it to treat peripheral artery disease (PAD) in the superficial femoral artery and proximal popliteal artery — with a low therapeutic drug dose and coating to transfer the drug into the tissue.